Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon2 and 4 bp deletion in exon2 and 5 bp deletion in exon2.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IFIT2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
IFIT2 also known as Interferon-Induced Protein with Tetratricopeptide Repeats 2 functions as a critical player in antiviral defense mechanisms. This protein possesses a molecular mass of approximately 54 kDa. IFIT2 expression occurs mostly in cells that respond to type I interferons and during viral infections. The protein locates within the cytoplasm where it acts by recognizing non-self RNA aiding in the inhibition of viral replication.
Biological function summary
The protein exerts its influence by binding to RNA molecules lacking 2'-O-methylation a modification that is usually absent in viral RNA. IFIT2 works as both a solo entity and as part of a larger complex that includes other members like IFIT1 and IFIT3. The coordination among these proteins helps modulate the immune response influencing protein synthesis regulation in cells that are under viral attack.
Pathways
IFIT2 plays an essential role in the innate immune response particularly the interferon signaling pathway. It contributes to this pathway through its interactions with other proteins ensuring the rapid activation of antiviral states. Furthermore IFIT2 also connects to the toll-like receptor (TLR) signaling pathway playing a part in recognizing viral components. Through these pathways IFIT2 typically associates with proteins like TLR3 which facilitate detection and response to viral pathogens.
Chronic viral infections and certain types of cancer show a significant connection with IFIT2. In viral diseases reduced or impaired IFIT2 activity can lead to increased viral replication exacerbating the infection. This protein also gets involved in mechanisms affecting cancer progression often in connection with pathways involving the protein p53 a well-known tumor suppressor. The interaction between IFIT2 and these disease-related pathways highlights its potential as a target for therapeutic development.
